Get started
MERCK & CO INCMERCK & CO INCMERCK & CO INC

MERCK & CO INC

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Bonds

MRKCL trade ideas

Undervalued Stock Series #3 : MERCKSeveral DCF valuations have suggested that the current price is on average +35% under the fair price. I took a quick look at their financials : their income last 5 years is positive, their revenue have grown last 5 years, their current asset > current liabilities and their Free Cash Flow can deal with their debts (i.e if they decided to pay off all of that debt, they could) Pipeline on phase 3 there are 25 products and 3 products under review (one of them is Anti-Viral COVID-19 molnupiravir (MK-4482) (US, EU)) -source : their website On the technicals, price is trading below the 100-200 EMA. The TSI shadow indicator still suggest we are still in a downtrend. As far as I am concerned, the lower the share price will go, the better. As long as the fundamentals still as it is now, I am happy the share price to go lower. I take note of last week's high as a level of interest as if this level is broken, it could be a sign of a momentum shift.
NYSE:MRKLong
by sufiansaid
20 years is a long wait, will Merck regain its glorious days ?Study this article carefully ! From a consumer perspective, if these pills are proven safe and effective with minimal side effects, I am sure the take up rate would be much higher , better still if they can be sold at pharmacies and other distribution outlets for easy access. Jabs take a longer time and the process is much longer as it requires the administration by a qualified staff from the healthcare sector. This takes time on both ends and delay the rates of vaccination to some extent. Let's wait patiently and see which stock shows a more bullish signs in the coming weeks.
NYSE:MRK
by dchua1969
Merck Stocks Have a 25% Growth PotentialToday we will review Merck & Co stocks as I have promised recently. The company announced the launch of the first oral medication against COVID-19 with proven efficiency. Let’s analyse the chart with the Merck stocks and their upside potential. When doing analysis it is traditionally better to start from the eldest timeframes to distinguish the existing trend. So, if we look at the monthly timeframe chart of Merck stocks we may find an upward trend that started in March 2009. We may also see a consolidation since January 2020 that lasted until September 2021, that is forming a triangle. This figure acts as a continuation sequence of the trend as the upward breakthrough has already been made. The breakthrough occurred on October 1, when the company announced successful clinical trial results of its anti-COVID-19 pill. This announcement was made a week before and no other news has been announced concerning this. This triangle provides a potential for Merck stocks to go to the $103.50-104 area. So, it is a potential gain of 25-26% from the current price. Moreover, the gap on October 1 is now acting as a key support level. Nevertheless, technically we may have a retest of the upper triangle margin at the $78.50-$79.30 area. But even if this retest does not happen, as it is not always the case, it is worth to consider adding these stocks to the portfolio. It should be noted that this technical pattern has been forming for several months and we should expect that the upside scenario would be effective for a while still. It may take 2-3 month, or even more, to reach the mentioned targets. However, such long-term technical patterns usually provide a good profit for those who are not looking for a checkered fortune.Merck has made contracts to deliver its pills not only in the United States, but also with other governments that are currently considering purchasing this new medication.
NYSE:MRKLong
by scavoanastasiia
$MRK Breaking out of two year accumulation zone into new ATH's.Merck is looking primed for a run into the $90's or higher after breaking 2 years of accumulation on the weekly chart. Ideally I want to see this hold the $84 support level and then bounce back through the all time high's. There is also huge call flow the past two days. One option chain that is getting some attention is Nov 19 $90 calls. Morgan Stanley also raised guidance from $88 to $90 and maintained equal-weight on the stock. Bullish.
NYSE:MRKLong
by CharlestonTrader
1
Merck & Co: Covid news linked breakout - BullishMerck & Co., Inc. develops pharmaceutical and vaccine products. It also offers healthcare solutions and vaccines addressing animal health. The company was founded in 1891 and is headquartered in Kenilworth, NJ. Average Analyst Rating : Moderate Buy : Price target : $92 Hedge Fund Trend: ▼ Hedge Funds Decreased Holdings by 8.8M Shares Last Quarter. Insider Activity : No Meaningful change last quarter News Sentiment last week: Very Bullish Technicals : Positive Merck and Ridgeback Therapeutics Inc.’s experimental oral antiviral treatment is being heralded as a pill with major upside potential in the fight against the COVID-19 pandemic. Malaysia is in talks to procure an experimental antiviral pill developed by Merck & Co for COVID-19 treatment, the health minister said on Saturday. Fundamental news brought sharp falls for the vaccine cos that have earlier made huge gains, the likes of PFEs and MRNA and others and MRK moved up sharply, breaking the range it was moving. Since its a news related move, more likely a new range would be created and previous resistance maybe difficult of breach. Most of the stocks that had fallen because of Covid lockdowns showed glimpses of finding investor interest as Airlines, Casinos & Gamings, Crusie Liners all made substantial moves. From a technical standpoint, its a Bollinger band blast on Daily charts. The candle formation can be tricky, but the weekly candle looks very strong Watch out for price action on Monday, dip buying should be a good strategy. I think another rotation in its way in terms of sector moves, ride this rally and watch out the Covid news regularly.
NYSE:MRKLong
by LoveForCharts